Amneal Pharmaceuticals, Inc. Total Debt 2017–2025
Amneal Pharmaceuticals, Inc. reported $2.57B of total debt (short- plus long-term borrowings) for fiscal 2025. That was 7.8% higher than fiscal 2024. Compared with fiscal 2020, the change was -7.5%.
| Fiscal year | Total Debt | Change (YoY) |
|---|---|---|
| FY 2025 | $2.57B | +7.8% |
| FY 2024 | $2.39B | -1.4% |
| FY 2023 | $2.42B | -7.7% |
| FY 2022 | $2.62B | -3.3% |
| FY 2021 | $2.71B | -2.5% |
| FY 2020 | $2.78B | +5.7% |
| FY 2019 | $2.63B | -0.8% |
| FY 2018 | $2.65B | +83.6% |
| FY 2017 | $1.44B | — |
Source: Amneal Pharmaceuticals, Inc. SEC filings — balance sheet (10-K). Computed deterministically; refreshed nightly (last updated August 2, 2026). Open AMRX 10-K filings at SEC EDGAR · Methodology · Download CSV.
How to read this history
Amneal Pharmaceuticals, Inc. reported $2.57B of total debt (short- plus long-term borrowings) for fiscal 2025. That was 7.8% higher than fiscal 2024. Compared with fiscal 2020, the change was -7.5%. Values remain missing when the cached filing does not disclose a comparable line item; they are never estimated. Stock splits, reorganizations and fiscal-calendar changes can reduce comparability.
Prepared and reviewed by the stockportfolio.pro research desk. Corrections: support@stockportfolio.pro.
See the full picture for Amneal Pharmaceuticals, Inc.
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeAmneal Pharmaceuticals, Inc. — frequently asked questions
What is Amneal Pharmaceuticals, Inc.'s total debt (short- plus long-term borrowings)?
Amneal Pharmaceuticals, Inc. (AMRX) reported total debt (short- plus long-term borrowings) of $2.57B for fiscal year 2025, per its SEC filings.
How has Amneal Pharmaceuticals, Inc.'s total debt (short- plus long-term borrowings) changed over time?
Between fiscal 2017 and 2025, AMRX's total debt (short- plus long-term borrowings) grew at roughly 7.5% per year (compound annual rate), from $1.44B to $2.57B.
Where does this data come from?
Figures are computed from Amneal Pharmaceuticals, Inc.'s official SEC filings (balance sheet (10-K)), refreshed nightly. Not investment advice.
More AMRX financial history
Full AMRX fundamentals page → · Analyze total debt (short- plus long-term borrowings) with a free tool → · All 1,500+ companies →